Literature DB >> 35418280

Bioactive Compounds and Diabetes Mellitus: Prospects and Future Challenges.

Md Mominur Rahman1, Md Rezaul Islam1, Fazle Rabbi1, Mohammad Touhidul Islam1, Sharifa Sultana1, Muniruddin Ahmed1, Aayush Sehgal2, Sukhbir Singh2, Neelam Sharma2, Tapan Behl2.   

Abstract

Diabetes mellitus is a metabolic condition that influences the endocrine framework. Hyperglycemia and hyperlipidemia are two of the most widely recognized metabolic irregularities in diabetes and two of the most well-known reasons for diabetic intricacies. Diabetes mellitus is a persistent illness brought about by metabolic irregularities in hyperglycemic pancreatic cells. Hyperglycemia can be brought about by an absence of insulin-producing beta cells in the pancreas (Type 1 diabetes mellitus) or inadequate insulin creation that does not work effectively (Type 2 diabetes mellitus). Present diabetes medication directs blood glucose levels in the systemic circulation to the typical levels. Numerous advanced prescription medicines have many negative results that can bring about unexpected severe issues during treatment of the bioactive compound from a different source that is beneficially affected by controlling and adjusting metabolic pathways or cycles. Moreover, a few new bioactive medications disengaged from plants have shown antidiabetic action with more noteworthy adequacy than the oral hypoglycemic agent that specialists have utilized in clinical treatment lately. Since bioactive mixtures are collected from familiar sources, they have a great activity in controlling diabetes mellitus. This study discusses bioactive compounds, their activity in managing diabetes mellitus, and their prospects. Though bioactive compounds have many health-beneficial properties, adequate clinical studies still need to acknowledge that they effectively manage diabetes mellitus. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Diabetes mellitus; bioactive compounds; hyperglycemia; hyperlipidemia; insulin; medications

Mesh:

Substances:

Year:  2022        PMID: 35418280     DOI: 10.2174/1381612828666220412090808

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.310


  4 in total

1.  Serum Biomarkers for Chronic Renal Failure Screening and Mechanistic Understanding: A Global LC-MS-Based Metabolomics Research.

Authors:  Xiaojuan Su; Ruru Ren; Lingling Yang; Chao Su; Yingli Wang; Jun Lu; Jing Liu; Rong Zong; Fangfang Lu; Gidion Wilson; Shuqin Ding; Xueqin Ma
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-30       Impact factor: 2.650

2.  Sodium Butyrate Attenuated Diabetes-Induced Intestinal Inflammation by Modulating Gut Microbiota.

Authors:  Liping Liu; Yuping Chen; Qin Wu; Anmei Shu; Jihu Sun
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-22       Impact factor: 2.650

Review 3.  Emerging Role of Neuron-Glia in Neurological Disorders: At a Glance.

Authors:  Md Mominur Rahman; Md Rezaul Islam; Md Yamin; Md Mohaimenul Islam; Md Taslim Sarker; Atkia Farzana Khan Meem; Aklima Akter; Talha Bin Emran; Simona Cavalu; Rohit Sharma
Journal:  Oxid Med Cell Longev       Date:  2022-08-22       Impact factor: 7.310

4.  Current Status and Trends of Research on Anthracycline-Induced Cardiotoxicity from 2002 to 2021: A Twenty-Year Bibliometric and Visualization Analysis.

Authors:  Yu Wang; Yifei Rao; Zhijian Lin; Rina Sa; Yuling Yin; Xiaomeng Zhang; Bing Zhang
Journal:  Oxid Med Cell Longev       Date:  2022-08-11       Impact factor: 7.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.